This compound is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It serves as a linker-payload system, where the Val-Cit-PAB segment acts as a cleavable linker, and MMAE is the potent cytotoxic agent. The linker is designed to remain stable in circulation but is cleaved by specific enzymes, such as cathepsin B, within the tumor cells, releasing the active drug to induce cell death. This approach enhances the precision of chemotherapy, minimizing damage to healthy tissues while maximizing the therapeutic effect on cancer cells. It is particularly valuable in treating hematological malignancies and solid tumors, offering a promising strategy for improving patient outcomes.